Molecular Sensing, Inc. (MSI) is commercializing Back-Scattering Interferometry (BSI), the world’s first label-free, conformation-sensitive, free-solution assay technology for biophysical characterization of small molecule interactions with complex drug targets. This includes crude membrane protein preparations and other biochemically intractable target binding assays in native-like, free-solution environments. MSI is introducing its commercial BSI instrument at ELRIG Drug Discovery 2014, the TruBind™ System 100 no tags or tethers for true binding characterization” . Please visit us at booth F 6.
